Clinical Trial

A Study of Belzutifan in Adolescent Participants With Solid Tumors (MK-9999-01E/LIGHTBEAM-U01)

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Researchers are looking for new ways to treat adolescents with locally advanced, unresectable, or metastatic solid tumors. Participants were enrolled into pheochromocytoma/paraganglioma (PPGL), wild type gastrointestinal stromal tumor (wtGIST), and Von Hippel-Lindau (VHL) disease-associated localized tumors cohorts: * PPGL are rare cancers that start in cells that make hormones in the adrenal glands * wtGIST is a less common type of cancer that starts in the digestive tract. Wild type means it does not have certain gene mutations (changes) * VHL disease-associated localized tumors are rare tumors caused by a certain gene mutation that may be passed down from parents to children * Locally advanced means the cancer has spread into nearby tissue * Unresectable means the cancer cannot be removed by surgery * Metastatic means the cancer has spread to other parts of the body The goal of the study is to learn about the safety of belzutifan and if people tolerate it.
Trial Details
NCT Number NCT07700758
Lead Sponsor Merck Sharp & Dohme LLC
Conditions Malignant Neoplasm
Enrollment 15 participants
Start Date 2026-11-23
Primary Completion 2034-01-02 (estimated)
Study Completion 2034-01-02 (estimated)
Updated on ClinicalTrials.gov 2026-08-13